News

Thomas J. Herzog, MD, discusses the importance of patients seeing a gynecologist oncologist or a sarcoma doctor for gynecologic perivascular epithelioid sarcomas.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.

In an interview with Targeted Oncology, Robert Reid, MD, discussed how the utilization of Ontada’s solutions helps to improve community-based research across the field of oncology.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

Rezatapopt treatment delivered responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.

Findings from the DUO-E study support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Ponatinib in combination with chemotherapy is now an approved treatment option for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the phase 3 LEAP-001, the combination of lenvatinib plus pembrolizumab improved progression-free survival and overall survival among patients with endometrial cancer.

Camrelizumab, nab-paclitaxel, and cisplatin showed statistically significant enhancements in pathologic complete responses in patients with resectable locally advanced esophageal squamous cell carcinoma.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.

If approved, denileukin diftitox could offer a valuable addition to the treatment landscape of relapsed/refractory cutaneous T-cell lymphoma.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

P-BCMA-ALLO1 was granted an FDA orphan drug designation for the treatment of patients with relapsed/refractory multiple myeloma and is being evaluated in a phase 1 trial.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

An increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.

This week's Targeted Pulse focuses on the latest in the treatment landscapes of small cell lung cancer, myeloma, and more.

Brian Slomovitz, MD, MS, FACOG, discusses the potential use of tisotumab vedotin-tftv in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.

When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.

In locally advanced cervical cancer, the combination of neoadjuvant tislelizumab plus chemotherapy was demonstrated to be safe with encouraging antitumor activity.

Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.

Olaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

An unprecendented survival benefit was demonstrated with dostarlimab plus in patients with microsatellite instability-high primary advanced or recurrent endometrial cancer.

Findings from the KEYNOTE-868 trial demonstrated a positive survival outcome with pembrolizumab plus chemotherapy across endometrial cancer subgroups.

Rates of cervical cancer across the United States vary due to social determinants of health.